SCHEMBL24423040

SCHEMBL24423040

COc1cc(-c2cc(C(=O)N3C(C)CC(C(=O)O)CC3C)n[nH]2)c(Cl)cn1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FFAR2 O15552 7/20 0.35
▸ CHRM4 P08173 3/20 0.32
▸ CCNE1 P24864 1/20 0.31
▸ CDK2 P24941 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ SMO Q99835 1/20 0.30
▸ PRKAG1 P54619 1/20 0.30
▸ PRKAA1 Q13131 1/20 0.30
▸ PRKAB1 Q9Y478 1/20 0.30
▸ OXTR P30559 1/20 0.30
▸ KDM5A P29375 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24424032 0.91 CHRM4 (0.35) FFAR2CHRM4CCNE1CDK2NPC1
SCHEMBL30630747 0.91 CHRM4 (0.35) FFAR2CHRM4CCNE1CDK2NPC1
SCHEMBL24423713 0.90 CYP4F2 (0.36) FFAR2CHRM4SMO
SCHEMBL29584640 0.90 CYP4F2 (0.36) FFAR2CHRM4SMO
SCHEMBL24423866 0.83 GAA (0.40) FFAR2NPC1ALDH1A1RAB9ASMO
SCHEMBL24423770 0.81 SCD (0.31) CHRM4OXTRKDM5A
SCHEMBL29583332 0.81 POLB (0.44) —
SCHEMBL24423448 0.81 MGLL (0.33) FFAR2CHRM4NPC1ALDH1A1CYP1A2
SCHEMBL24423714 0.81 MGLL (0.33) FFAR2CHRM4NPC1ALDH1A1CYP1A2
SCHEMBL29585305 0.81 MGLL (0.33) FFAR2CHRM4NPC1ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4240736-A1 PPAR GAMMA MODULATORS AND METHODS OF USE Eisai R&D Management Co., Ltd. (JP) 2023-09-13 — — EP disclosed
CN-116635380-A PPARgamma modulators and methods of use 卫材R&D管理有限公司 2023-08-22 — — CN disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 — — US disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 — — WO disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE PPARG, PPARA, PPARD FFAR2 16/4885CHRM4 1569/4885CCNE1 3902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback